Peripheral neuropathy symptoms, pain, and functioning in previously treated multiple myeloma patients treated with selinexor, bortezomib, and dexamethasone

TY - JOUR

T1 - Peripheral neuropathy symptoms, pain, and functioning in previously treated multiple myeloma patients treated with selinexor, bortezomib, and dexamethasone

AU - Sanchez, Larysa

AU - Leleu, Xavier

AU - Beaumont, Jennifer L.

AU - Yu, Hailin

AU - Hudgens, Stacie

AU - Simonova, Maryana

AU - Auner, Holger W.

AU - Quach, Hang

AU - Delimpasi, Sosana

AU - Špička, Ivan

AU - Pour, Ludĕk

AU - Kriachok, Iryna

AU - Dimopoulos, Meletios A.

AU - Usenko, Ganna

AU - Hájek, Roman

AU - Benjamin, Reuben

AU - Sinha, Dinesh Kumar

AU - Venner, Christopher

AU - Illmer, Thomas

AU - Garg, Mamta Krishnan

AU - Stevens, Don Ambrose

AU - Jagannath, Sundar

AU - Levy, Moshe

AU - Anderson, Larry D.

AU - Bahlis, Nizar Jacques

AU - Facon, Thierry

AU - Cavo, Michele

AU - Chai, Yi

AU - Ma, Xiwen

AU - Tang, Shijie

AU - Leong, Hoyee

AU - Shah, Jatin

AU - Shacham, Sharon

AU - Kauffman, Michael

AU - Richardson, Paul

AU - Grosicki, Sebastian

N1 - Funding Information: Xavier Leleu reports honoraria from AbbVie, Amgen, Bristol‐Myers Squibb, Carsgen Therapeutics Ltd, Celgene, Gilead Sciences, Janssen‐Cilag, Karyopharm Therapeutics, Merck, Mundipharma, Novartis, Oncopeptides, Pierre Fabre, Roche, Sanofi, and Takeda and non‐financial support from Takeda. Jennifer L Beaumont, Hailin Yu, and Stacie Hudgens are employees of Clinical Outcomes Solutions which received funding to conduct the analytic planning and execution activities associated with this research. Holger W. Auner reports an advisory role for Takeda and Karyopharm; a grant from Amgen; and a speaker's bureau role for Janssen. Hang Quach reports grants from and an advisory board role for Amgen, Celgene, Karyopharm, GlaxoSmithKline; non‐financial support and research drug supply from Sanofi; and an advisory board role for Janssen Cilag and Specialized Therapeutics. Sosana Delimpasi has received honoraria from Janssen, Takeda, Amgen, and Celgene. Ivan Špička reports personal fees from Janssen‐Cilag, Takeda, Sanofi Aventis, and Novartis; personal fees and non‐financial support from Colgene, BMS, and Amgen. Iryna Kriachok reports a consulting role, an advisory role, and a speaker's bureau role for Takeda, Janssen, Roche, AbbVie, and MSD; and travel support by Takeda, MSD, Roche, AbbVie, and Janssen. Roman Hájek has had a consultant or advisory relationship with Janssen, Amgen, Celgene, AbbVie, BMS, Novartis, PharmaMar, and Takeda; has received honoraria from Janssen, Amgen, Celgene, BMS, PharmaMar, and Takeda; and has received research funding from Janssen, Amgen, Celgene, BMS, Novartis, and Takeda. Christopher Venner has received honoraria from BMS/Celgene, Janssen, Sanofi, Amgen, GSK, and Takeda. Mamta Krishnan Garg reports support for attending conferences from Takeda; an advisory role for Amgen, Takeda, Jansen, Novartis, and Celgene; and a speaker's bureau role for Janssen. Sundar Jagannath reports consulting services for AbbVie, Bristol‐Myers Squibb, Janssen Pharmaceuticals, and Merck and involvement in clinical trials as Principal Investigator of Karyopharm, Intas Pharmaceuticals, and Dr Reddy's Laboratories. Moshe Levy reports receiving consulting fees and lecture fees from Takeda, Celgene, Seattle Genetics, AbbVie, Jazz Pharmaceuticals, Gilead Sciences, Bristol‐Myers Squibb, Amgen, Spectrum Pharmaceuticals, and Janssen. Larry D. Anderson Jr. reports honoraria from advisory board activity from the following: GSK, Amgen, Janssen, BMS/Celgene, Karyopharm, and Oncopeptides. Nizar Jacques Bahlis reports grants and personal fees from Celgene; personal fees from Janssen, Amgen, Takeda, Abbvie, GSK and Karyopharm. Thierry Facon reports an advisory board role for Karyopharm, Amgen, Roche, and Oncopeptides; and an advisory board role and a speaker's bureau role for Janssen, Celgene/BMS, and Takeda. Yi Chai, Xiwen Ma, Shijie Tang, Hoyee Leong, and Michael Kauffman are employees of and stockholders of Karyopharm. Jatin Shah reports being employed by and owning stock in Karyopharm Therapeutics and advisory board role for GSK, Celbene/BMS, Amgen, Oncopeptides, and Karyopharm. Sharon Shacham reports being employed by and owning stock in Karyopharm Therapeutics, holding patents (8 999 996, 9 079 865, 9 714 226, PCT/US12/048319, and I574957) on hydrazide‐containing nuclear transport modulators and uses, and holding pending patents (PCT/US12/048319, 499/2012, PI20102724, and 2 012 000 928) on hydrazide‐containing nuclear transport modulators and uses. Paul Richardson reports receiving grant support and honoraria from Oncopeptides, Celgene, and Takeda, grant support from Bristol‐Myers Squibb, and honoraria from Amgen, Janssen, and Karyopharm Therapeutics. All other authors declare no conflict of interest.

PY - 2021/10/1

Y1 - 2021/10/1

UR - http://www.scopus.com/inward/record.url?scp=85109791260&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85109791260&partnerID=8YFLogxK

U2 - 10.1002/ajh.26282

DO - 10.1002/ajh.26282

M3 - Letter

C2 - 34161627

AN - SCOPUS:85109791260

SN - 0361-8609

VL - 96

SP - E383-E386

JO - American Journal of Hematology

JF - American Journal of Hematology

IS - 10

ER -